SCHEMBL2131850

SCHEMBL2131850

NC(=O)c1nc2cc(OCc3ccccc3)ccc2[nH]1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP2C9 P11712 1/20 0.55
HPGD P15428 1/20 0.55
SRD5A2 P31213 1/20 0.55
HSD17B10 Q99714 1/20 0.55
CHEK2 O96017 1/20 0.54
FAAH O00519 2/20 0.53
PDGFRB P09619 1/20 0.52
PDGFRA P16234 1/20 0.52
PARP10 Q53GL7 1/20 0.51
CFD P00746 1/20 0.50
CYP3A4 P08684 1/20 0.48
FLT3 P36888 1/20 0.47
PLAU P00749 1/20 0.46
PLAT P00750 1/20 0.46
ALOX5 P09917 1/20 0.46
MAOB P27338 5/20 0.45
MAOA P21397 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4466653 0.90 ALDH1A1 (0.61) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL2133843 0.88 MAOB (0.59) FAAHPARP10MAOBMAOA
SCHEMBL2132114 0.88 FFAR1 (0.45) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL2134219 0.87 MAOB (0.48) FAAHMAOBMAOA
SCHEMBL2132145 0.85 MAOB (0.61) CHEK2MAOBMAOA
SCHEMBL3064556 0.82 CHEK2 (0.50) KDM4EALDH1A1CYP1A2HPGDHSD17B10
SCHEMBL2131853 0.80 XDH (0.55) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL4470392 0.78 NPC1 (0.52) KDM4EALDH1A1CYP1A2CYP2C9HPGD
SCHEMBL2133081 0.78 MAOB (0.49) KDM4EALDH1A1CYP1A2HPGDFAAH
SCHEMBL9529962 0.78 CYP3A4 (0.54) KDM4EALDH1A1CYP1A2CYP2C9HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8350039-B2 Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2013-01-08 US claimed
US-8350039-B2 Substituted isoquinoline derivatives, pharmaceutical compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2013-01-08 US disclosed
US-20120101125-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS HIGH POINT PHARMACEUTICALS, LLC (US) 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101125-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS BACE1, BACE2, APP KDM4E 3840/4885ALDH1A1 3187/4885CYP1A2 839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.